Gilles Salles

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi request reprint Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France
    Clin Lymphoma Myeloma 8:356-8. 2008
  2. doi request reprint Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon, Lyon, France
    Leuk Lymphoma 51:399-405. 2010
  3. pmc Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
    Anne Sophie A S Michallet
    Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France
    J Hematol Oncol 6:45. 2013
  4. doi request reprint Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study
    Gilles A Salles
    Hospices Civils de Lyon Université de Lyon, 165 Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    J Clin Oncol 31:2920-6. 2013
  5. doi request reprint Current and future management of follicular lymphoma
    Gilles Salles
    Hospices Civils de Lyon, Universite Lyon 1, Pierre Benite, France
    Int J Hematol 96:544-51. 2012
  6. doi request reprint Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Gilles Salles
    Hospices Civils de Lyon, Hematologie, Universite de Lyon, Unité Mixte de Recherche UMR 5239, Centre National de la Recherche Scientifique CNRS, Pierre Benite, France
    Blood 119:5126-32. 2012
  7. ncbi request reprint [Chronic lymphoproliferative disorders]
    Gilles Salles
    Service d hématologie Centre hospitalier Lyon Sud, 69495 Pierre Benite
    Rev Prat 52:966-71. 2002
  8. doi request reprint Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
    Gilles Salles
    Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France
    Blood 117:7070-8. 2011
  9. ncbi request reprint Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
    Gilles Salles
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 112:4824-31. 2008
  10. doi request reprint Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
    Gilles Salles
    Hospices Civils de Lyon, Universite Claude Bernard, UMR CNRS5239, Pierre Benite, France
    Lancet 377:42-51. 2011

Detail Information

Publications92

  1. ncbi request reprint Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France
    Clin Lymphoma Myeloma 8:356-8. 2008
    ..Herein, we briefly review the spectrum of immunodeficiency-associated lymphoproliferative disorders (LPDs), discuss the immune deficit induced by rituximab, and speculate on its possible association with EBV reactivation in this patient...
  2. doi request reprint Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study
    Anna Johnston
    Department of Hematology, Hospices Civils de Lyon, Lyon, France
    Leuk Lymphoma 51:399-405. 2010
    ..Relapse occurring after rituximab-containing therapy appears to be more aggressive than that occurring after chemotherapy alone. The outcome of retreatment, in terms of progression-free survival, is similar to that of primary treatment...
  3. pmc Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
    Anne Sophie A S Michallet
    Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France
    J Hematol Oncol 6:45. 2013
    ..Our aim was to revisit the outcome of patients with localized FL in the rituximab era...
  4. doi request reprint Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study
    Gilles A Salles
    Hospices Civils de Lyon Université de Lyon, 165 Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    J Clin Oncol 31:2920-6. 2013
    ....
  5. doi request reprint Current and future management of follicular lymphoma
    Gilles Salles
    Hospices Civils de Lyon, Universite Lyon 1, Pierre Benite, France
    Int J Hematol 96:544-51. 2012
    ..Since most patients will likely survive for many years, the quality and duration of response as well as the short- and long-term side effects of the treatments should be carefully weighted during this prolonged therapeutic management...
  6. doi request reprint Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Gilles Salles
    Hospices Civils de Lyon, Hematologie, Universite de Lyon, Unité Mixte de Recherche UMR 5239, Centre National de la Recherche Scientifique CNRS, Pierre Benite, France
    Blood 119:5126-32. 2012
    ..Data from this study suggest that GA101 was well tolerated and demonstrated encouraging activity in patients with previously treated NHL up to doses of 2000 mg. This trial is registered at www.clinicaltrials.gov as NCT00517530...
  7. ncbi request reprint [Chronic lymphoproliferative disorders]
    Gilles Salles
    Service d hématologie Centre hospitalier Lyon Sud, 69495 Pierre Benite
    Rev Prat 52:966-71. 2002
    ..A better definition of these entities should allow to clarify therapeutic recommendations before more efficient treatments become available...
  8. doi request reprint Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
    Gilles Salles
    Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France
    Blood 117:7070-8. 2011
    ..These data demonstrate that the IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy...
  9. ncbi request reprint Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
    Gilles Salles
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 112:4824-31. 2008
    ..This study's clinical trial was registered at the National Institutes of Health website as no. NCT00136552...
  10. doi request reprint Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
    Gilles Salles
    Hospices Civils de Lyon, Universite Claude Bernard, UMR CNRS5239, Pierre Benite, France
    Lancet 377:42-51. 2011
    ..We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen...
  11. doi request reprint Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index
    Ewa Lech-Maranda
    Equipe Pathologie des Cellules Lymphoïdes, UMR CNRS 5239, Universite Claude Bernard, Lyon, France
    Arch Immunol Ther Exp (Warsz) 58:131-41. 2010
    ..This model may help to identify patients in a given IPI risk group for whom more accurate and risk-adapted treatment could be advised...
  12. ncbi request reprint Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis
    Herve Ghesquieres
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d Hematologie, France
    J Clin Oncol 24:5234-41. 2006
    ..The characteristics and prognosis of these particular DLBCL are not well known...
  13. ncbi request reprint Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud
    Bernard Lemieux
    Hematology Department, Hospices Civils de Lyon, Universite Claude Bernard, Pierre Benite, France
    Hematol J 5:467-71. 2004
    ..3 months, P = 0.09). The second treatment was well tolerated. Thus, a second treatment with rituximab should be considered, alone or in combination with chemotherapy, for patients who progress after a first response to rituximab...
  14. doi request reprint Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte
    Emmanuel Bachy
    Service d Hematologie, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    J Clin Oncol 28:822-9. 2010
    ..Therefore, response-adapted therapy aiming to achieve a CR should be considered as first-line treatment...
  15. pmc CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases
    Lucile Baseggio
    Laboratoire d Hématologie Cellulaire Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon
    Haematologica 95:604-12. 2010
    ....
  16. pmc Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
    Emmanuel Bachy
    Hospices Civils de Lyon and Université Lyon 1, France
    Haematologica 98:1107-14. 2013
    ..Long-term follow up of patients with follicular lymphoma treated in the FL2000 study confirms the sustained clinical benefit of rituximab without long-term toxicity...
  17. doi request reprint In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia
    Lucile Baseggio
    Service d Hematologie Biologique, UMR5239 Pathologies des cellules lymphoïdes, Universite Claude Bernard, Lyon, France
    Br J Haematol 158:489-98. 2012
    ..Moreover, most of these CLLs harboured a low mutation load of BCL6 gene and unmutated FAS (CD95) loci, which points to a post-germinal-centre cellular origin...
  18. ncbi request reprint Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin's lymphoma
    Celine Bencimon
    Laboratoire d Auto Immunite, Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    Ann N Y Acad Sci 1050:319-26. 2005
    ..In addition to the usefulness of anti-CENP-F aAbs as a marker for some NHL subgroups, prospective studies may be important to evaluate the predictive value of anti-CENP-F aAbs for the development of carcinomas...
  19. ncbi request reprint Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
    Alexandra Traverse-Glehen
    Service d Anatomie Pathologique Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
    Blood 111:2253-60. 2008
    ..These results, as well as the clinical evolution, show that those lymphoma cases represent a homogeneous group distinct from SMZL and reminiscent of hairy cell leukemia variant, perhaps corresponding to a separate lymphoma entity...
  20. ncbi request reprint Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis
    Catherine Thieblemont
    Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Blood 103:2727-37. 2004
    ..This study demonstrates that SLL, splenic MZL, and MCL possess specific transcriptional profiles that may be relevant to the pathogenesis and the diagnosis of these histologic subtypes...
  21. ncbi request reprint Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients
    Catherine Thieblemont
    Hematology Department, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Clin Lymphoma 3:41-7. 2002
    ..We conclude that splenectomy is an efficient treatment for splenic MZL, but that it may be delayed until the occurrence of symptoms or cytopenia...
  22. doi request reprint Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases
    Alexandra Traverse-Glehen
    Hospices Civils de Lyon, Service d Anatomie Pathologique, Centre Hospitalier Lyon Sud, Universite Lyon 1, Pierre Benite, France
    Histopathology 62:876-93. 2013
    ..To describe 76 cases of splenic marginal zone lymphoma (SMZL), including correlations with clinical and other characteristics...
  23. doi request reprint Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    Equipe d Accueil Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, Lyon, France
    Arch Immunol Ther Exp (Warsz) 61:165-74. 2013
    ..VEGF may be a useful marker for selecting the patients for whom new treatment approaches, especially those based on VEGF inhibitors, could be recommended...
  24. doi request reprint CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma
    Lucile Baseggio
    Laboratoire d Hématologie cellulaire, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Mod Pathol 24:993-1003. 2011
    ..Consequently, if ICOS constitutes an additional feature for the diagnosis of angioimmunoblastic T-cell lymphoma, it appears less sensitive than CD10 expression for the detection of circulating neoplastic T cells...
  25. ncbi request reprint Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
    Francoise Berger
    Pathology Service, Centre Hospitalier Lyon Sud, Equipe d Accueil 3737, Pathologie des Cellules Lymphoides, Universite Claude Bernard, Lyon, France
    Clin Lymphoma 5:220-4. 2005
    ..Molecular IgVH gene analysis has confirmed this heterogeneity, particularly within SMZL, with mutated and unmutated cases. Further studies are needed to clarify the pathogenesis of these MZLs and their relationship with LPL...
  26. ncbi request reprint Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection
    Alexandra Traverse-Glehen
    Equipe Accueil 3737 Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, France
    Haematologica 90:470-8. 2005
    ..To clarify the relationship between splenic (SMZL) and nodal marginal zone (NMZL) lymphomas, we analyzed immunoglobulin variable heavy chain (VH) gene usage and mutation patterns in these tumors...
  27. ncbi request reprint Improving cancer patient care with combined medication error reviews and morbidity and mortality conferences
    Florence Ranchon
    Department of Clinical Oncology Pharmacy, Groupement Hospitalier Sud, Hospices Civils de Lyon, Lyon, France
    Chemotherapy 59:330-7. 2013
    ..This multidisciplinary work is indispensable to improve future patient management through the critical analysis of past medical errors. © 2014 S. Karger AG, Basel. ..
  28. doi request reprint First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis
    Anne Sophie Michallet
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Department of Hematology, 165 Chemin du Grand Revoyet, 69495 Pierre Benite, France Electronic address
    J Geriatr Oncol 4:141-7. 2013
    ..As a result, no definitive treatment exists for elderly patients, especially less medically fit patients...
  29. ncbi request reprint Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    Equipe d Accueil 3737 Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, Lyon, France
    Blood 103:3529-34. 2004
    ..76, P =.00035) and OS (RR =.78, P =.0015). These results indicate that IL-10 production contributes to the clinical course of DLBCL and that this phenomenon involves a substantial genetic component...
  30. ncbi request reprint Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
    Catherine Thieblemont
    Service d Hematologie Clinique, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Cancer 104:1434-41. 2005
    ..The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high-dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL)...
  31. ncbi request reprint Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France
    Pascal Seve
    Department of Internal Medicine, Lyon Civil Hospices, Lyon, France
    Eur J Gastroenterol Hepatol 16:1361-5. 2004
    ..We sought to determine whether such an association could be found in patients treated in the Rhone-Alpes region in south-east France. Our main interest was to identify histological subtypes preferentially linked to HCV...
  32. ncbi request reprint Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma
    Sophie Gazzo
    Service d Hematologie Biologique, Centre Hospitalier Lyon Sud Hospices Civils de Lyon et Université Claude Bernard Lyon I, EA 3737, 69495 Pierre Benite, Cedex 69495, France
    Cancer Genet Cytogenet 175:159-65. 2007
    ..This also confirms the localization in the vicinity of band 7q32 of putative candidate gene(s) involved in the pathogenic development of the disease...
  33. ncbi request reprint Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL)
    Catherine Thieblemont
    Hematology Departement, Hospices Civils de Lyon, Claude Bernard University, 69495 Pierre Benite, France
    Leuk Lymphoma 45:711-4. 2004
    ..In conclusion, maintenance alemtuzumab therapy seems to increase the time to progression and the survival, without adding hematological toxicities and infectious complications. More patients are needed to confirm this observation...
  34. ncbi request reprint Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients
    Florence Lachenal
    Hospices Civils de Lyon, Department of Internal Medicine, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Medicine (Baltimore) 86:282-92. 2007
    ..The current study underlines the diversity of presenting manifestations of angioimmunoblastic T-cell lymphoma...
  35. ncbi request reprint Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
    Herve Ghesquieres
    Centre Leon Berard, Lyon, France
    Blood 120:2650-7. 2012
    ..The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582...
  36. pmc Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells
    Amel Chebel
    Universite Lyon 1, CNRS UMR 5239, Ecole Normale Supérieure ENS, Universite Claude Bernard, Hospices Civils de Lyon, Faculté Lyon Sud, Oullins 69921
    J Biol Chem 284:35725-34. 2009
    ..Thus, we show for the first time the direct involvement of NFAT1 in the transcriptional regulation of hTERT...
  37. ncbi request reprint Cytogenetic and molecular analysis of 12 cases of primary cutaneous marginal zone lymphomas
    Arnaud de la Fouchardiere
    Laboratoire de Cytogénétique et Biologie Moléculaire, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Am J Dermatopathol 28:287-92. 2006
    ..These data also underline that fluorescence in situ analysis on routine skin punch biopsies represents a reliable tool for the detection of chromosomal changes, but requires consistent dermal infiltration...
  38. ncbi request reprint Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies
    Fadela Bouafia
    Service d Hématologie and Service de Biochimie, Centre Hospitalier Lyon Sud, Chemin du Grand Revoyet, 69495 Pierre Benite, France
    Bull Cancer 91:E229-40. 2004
    ..We conclude that there are characteristic alterations in serum LDH profiles in patients with haematopoietic malignancies and that some of these may be more interesting in terms of prognostic value than total serum LDH...
  39. pmc Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma
    Adrien Chauchet
    Department of Hematology, Centre Hospitalier Universitaire Lyon Sud, Pierre Benite, France
    J Hematol Oncol 5:27. 2012
    ..Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors...
  40. pmc High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia
    Sandrine Hayette
    Service d Hematologie Biologique, Centre Hospitalier Lyon Sud, Pierre Benite France, Hospices Civils de Lyon, Lyon, France
    PLoS ONE 7:e51527. 2012
    ..Its quantification should be implemented to the genetic profile used to stratify patients for therapeutical strategies and should be useful to identify patients who may benefit from therapy based on demethylating agents...
  41. ncbi request reprint Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity
    Alexandra Traverse-Glehen
    Service d Anatomie Pathologique, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Benite, France
    Discov Med 13:253-65. 2012
    ..This review will report literature data and discuss the differential diagnosis, particularly with HCL-V...
  42. doi request reprint Predictors of prescription errors involving anticancer chemotherapy agents
    Florence Ranchon
    Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department Université Lyon 1, Ecole Doctorale Interdisciplinaire Sciences Santé, Lyon, France
    Eur J Cancer 48:1192-9. 2012
    ..The majority of medication errors that harm patients relate to the prescribing process. Our study aimed to identify the predictors of prescription errors involving anticancer chemotherapy agents...
  43. ncbi request reprint Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma
    Ewa Lech-Maranda
    Equipe d Accueil Pathologie des Cellules Lymphoïdes, Universite Claude Bernard, Lyon, France
    Eur Cytokine Netw 17:60-6. 2006
    ..The plasma concentration of IL-10 may be a useful marker for evaluation of disease activity...
  44. doi request reprint Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL
    Emmanuel Bachy
    Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Pierre Bénite 69495, France
    Best Pract Res Clin Haematol 24:257-70. 2011
    ..This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment...
  45. pmc Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy
    Matthew J Maurer
    Matthew J Maurer, Hervé Ghesquières, Thomas E Witzig, Carrie A Thompson, Ivana N Micallef, William R Macon, Paul J Kurtin, Cristine Allmer, Susan L Slager, Thomas M Habermann, and James R Cerhan, Mayo Clinic, Rochester, MN Hervé Ghesquières and Emmanuelle Nicolas Virelizier, Centre Léon Bérard Hervé Ghesquières and Gilles Salles, Universite Claude Bernard, Unité Mixte de Recherche UMR, Centre National de la Recherche Scientifique 5239, Lyon Jean Philippe Jais, Institut National de la Santé et de la Recherche Médicale INSERM UMR S 872, Necker Hospital, Assistance Publique Hopitaux de Paris Richard Delarue, Necker Hospital Thierry Jo Molina, Paris Descartes University, Paris Centre University Hospital, Paris Corinne Haioun, Henri Mondor Hospital, Universite Paris Est, Créteil Frédéric Peyrade, Centre Antoine Lacassagne, Nice Olivier Fitoussi, Polyclinique Bordeaux Nord, Bordeaux Gilles Salles, Hospices Civils de Lyon
    J Clin Oncol 32:1066-73. 2014
    ..We evaluated the timing and type of events in newly diagnosed DLBCL and compared patient outcome with reference population data...
  46. ncbi request reprint Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma
    Sophie Gazzo
    Laboratoire Central d Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, Lyon, France
    Haematologica 88:31-8. 2003
    ..Fluorescent in situ hybridization (FISH) experiments were then performed to characterize the breakpoints further and to delineate the extent of the 3q gained region more accurately...
  47. doi request reprint Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
    Bertrand Coiffier
    Hematology, Hospices Civils de Lyon, Lyon, France
    Lancet Oncol 12:773-84. 2011
    ..We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting...
  48. ncbi request reprint Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation
    Adeline Augereau
    Epigenetic and Telomeric Regulations, Lyon Sud Medicine Faculty, Lyon 1 University, Centre National de la Recherche Scientifique CNRS Unité Mixte de Recherche UMR 5239, Pierre Benite, France
    Blood 118:1316-22. 2011
    ..0464) and TINF2 (coding for TIN2; P = .0177). We propose that telomeric deprotection in the early step of CLL is not merely the consequence of telomere shortening but also of shelterin alteration...
  49. ncbi request reprint Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants
    Judith Trotman
    Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney, Sydney, Australia
    J Clin Oncol 29:3194-200. 2011
    ..We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study...
  50. pmc Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts
    Herve Ghesquieres
    Onco Hematology, Centre Leon Berard, UMR CNRS 5239, Universite Lyon 1, Lyon, France Health Sciences Research, Mayo Clinic, Rochester, MN, USA Electronic address
    Cytokine 64:523-31. 2013
    ..Germline single nucleotide polymorphisms (SNPs) in immune genes have been correlated with cytokine production and function...
  51. doi request reprint Administration of anticancer drugs: exposure in hospital nurses
    Catherine Rioufol
    University Claude Bernard Lyon, Lyon, France Hospices civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Lyon, France Electronic address
    Clin Ther 36:401-7. 2014
    ..Even though anticancer drugs are prepared in dedicated pharmaceutical units, nurses remain exposed to cytotoxic agents during administration to patients...
  52. ncbi request reprint [Prognostic factors in lymphomas]
    Emmanuel Bachy
    Hospices Civils de Lyon, Universite Claude Bernard, Service d hématologie Centre hospitalier Lyon Sud, 69496 Pierre Bénite Cedex
    Rev Prat 60:65-8. 2010
    ..Numerous biomarkers obtained on fresh or frozen tissue using molecular techniques are currently described and may help to optimize the clinical care of lymphoma patients tomorrow...
  53. ncbi request reprint Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia
    Delphine Poncet
    Laboratoire de Biologie Moleculaire et de Cellule, Centre National de la Recherche Scientifique UMR5239, IFR128, Faculté de médecine Lyon Sud, Universite Lyon 1, Lyon, France
    Blood 111:2388-91. 2008
    ..001). This differential expression pattern suggests that both telomerase down-regulation and changes in telomeric proteins composition are involved in the pathogenesis of B-CLL...
  54. ncbi request reprint Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma
    Alexandra Traverse-Glehen
    Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France
    Oncology (Williston Park) 26:92-9, 103-4. 2012
    ....
  55. ncbi request reprint Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001
    Catherine Thieblemont
    Hematology Department, Hospices Civils de Lyon Claude Bernard University 69495 Pierre Benite, France
    Leuk Lymphoma 44:257-62. 2003
    ..Considering the natural bias of a retrospective analysis, surgery or chemotherapy was associated with a similar outcome in patients with MALT lymphoma after antibiotics failure...
  56. ncbi request reprint CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    ..We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma...
  57. ncbi request reprint Maintenance therapy in follicular lymphoma
    Anne Sophie Michallet
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, Lyon, France
    Curr Opin Oncol 23:449-54. 2011
    ..This article reviews the potential benefit of maintenance therapy for patients with follicular lymphoma...
  58. doi request reprint Prognostic systems for lymphomas
    Anna Johnston
    Service d Hematologie, Hospices Civils de Lyon, 69495 Pierre Benite, Lyon, France
    Hematol Oncol Clin North Am 22:839-61, viii. 2008
    ..The current challenge, translating these molecular findings into clinical practice, requires the validation of those biomarkers in large cohorts of patients...
  59. doi request reprint The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate
    Nicolas Rachinel
    Faculté de Médecine Lyon Sud Charles Mérieux, 165, Chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France
    Curr Hematol Malig Rep 4:196-201. 2009
    ..Blocking the cross-talk between the tumor microenvironment and lymphoma cells may thus represent a promising new strategy for treating B-cell malignancies...
  60. doi request reprint S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53
    Wei Wen Chien
    Universite Claude Bernard Lyon 1, CNRS UMR 5239, ENS HCL, Faculte de Medecine, Pierre Benite, France
    Cell Cycle 9:3286-96. 2010
    ....
  61. ncbi request reprint Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation
    Tagrid Kaddar
    LBMC, CNRS UMR5239, IFR128, Faculté de médecine Lyon Sud, Universite Lyon 1, Pierre Benite, France
    Biol Cell 101:511-24. 2009
    ..These data prompted us to search for and validate novel targets of miR-16...
  62. ncbi request reprint t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma
    Sandrine Roulland
    Sandrine Roulland, Ester Morgado, Stéphanie Sungalee, Nathalie Jouve, and Bertrand Nadel, Aix Marseille Universite, Institut National de la Santé et de la Recherche Médicale Inserm U1104, and Centre National de la Recherche Scientifique CNRS Unités Mixtes de Recherche UMR 7280, Marseille Philippe Solal Celigny, Jean Bernard Center, Le Mans Philippe Colombat, Bretonneau University Hospital, Tours Françoise Clavel Chapelon, INSERM U1018 Centre de Recherche en Epidémiologie et Santé des Populations, Villejuif Pietro Ferrari and Isabelle Romieu, International Agency for Research on Cancer, Lyon Gilles Salles, Hospices Civils de Lyon, Universite de Lyon, UMR CNRS 5239, Pierre Benite, France Rachel S Kelly, Petra H M Peeters, Roel Vermeulen, Elio Riboli, and Paolo Vineis, School of Public Health, Imperial College London, London Kay Tee Khaw, University of Cambridge Nick Wareham, Institute of Metabolic Science, Cambridge Timothy J Key and Ruth C Travis, University of Oxford, Oxford, Photocatalysis and Photoreaction Engineering
    J Clin Oncol 32:1347-55. 2014
    ..Here we sought to determine whether t(14;18)-positive cells in healthy individuals represent tumor precursors and whether their detection could be used as an early predictor for FL...
  63. pmc Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
    Florence Ranchon
    Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite Université Lyon 1, EMR UCBL HCL 3738, Lyon, France
    BMC Cancer 11:478. 2011
    ..This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and costs...
  64. ncbi request reprint Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors
    Cecilia Frecha
    INSERM U758, Human Virology Department, Universite de Lyon, Ecole Normale Superieure de Lyon, Lyon, France
    Blood 114:3173-80. 2009
    ..These new LVs will facilitate antibody production and the study of gene functions in these healthy and cancer immune cells...
  65. ncbi request reprint Treatment approaches to asymptomatic follicular lymphoma
    Clémentine Sarkozy
    hospices civils de Lyon HCL, Universite Claude Bernard Lyon 1, Service d Hematologie, centre hospitalier Lyon Sud CHLS, Pierre Benite, France
    Expert Rev Hematol 6:747-58. 2013
    ..Based on these options, the challenge is to preserve patient quality of life and prolong survival: from the patient's perspective, his/her opinion is therefore of significant importance...
  66. doi request reprint PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study
    Christelle Tychyj-Pinel
    Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de Medecine Nucleaire, Pierre Benite, France
    Eur J Nucl Med Mol Imaging 41:408-15. 2014
    ..Lancet 377:42-51, 2011; Trotman et al., J Clin Oncol 29:3194-3200, 2011) to scan review at local centres...
  67. ncbi request reprint Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma
    Stephanie Guyomard
    Department of Autoimmunity Department of Clinical Hematology Department of Internal Medicine, Centre Hospitalier Lyon Sud, HCL, Pierre Benite, France
    Br J Haematol 123:90-9. 2003
    ....
  68. pmc Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma
    Delphine Rolland
    Universite Joseph Fourier, INSERM U836 Equipe 7, Grenoble, France
    Cancer Chemother Pharmacol 61:855-63. 2008
    ..The cytotoxic activity of the farnesyltranseferase inhibitor R115777 was evaluated in cell lines representative of mantle cell lymphoma (MCL)...
  69. ncbi request reprint Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
    Stefano Monti
    The Broad Institute, Cambridge, MA, USA
    Blood 105:1851-61. 2005
    ..These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets...
  70. ncbi request reprint Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma
    Bertrand Coiffier
    Blood 104:1584-5; author reply 1585-6. 2004
  71. ncbi request reprint Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial
    Christophe Ferme
    Groupe d Etudes des Lymphomes de l Adulte, Hopital Saint Louis, Paris, France
    J Clin Oncol 20:467-75. 2002
    ....
  72. ncbi request reprint The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
    Kerry J Savage
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:3871-9. 2003
    ..In almost all cases, c-REL was localized to the nucleus, consistent with activation of the NF-kappa B pathway. These studies identify a molecular link between MLBCL and cHL and a shared survival pathway...
  73. ncbi request reprint Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
    Christophe Ferme
    Department of Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France
    N Engl J Med 357:1916-27. 2007
    ..Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure...
  74. ncbi request reprint Splenic marginal-zone lymphoma: a distinct clinical and pathological entity
    Catherine Thieblemont
    Haematology Department, Centre Hospitalier Lyon Sud, Pierre, Benite, France
    Lancet Oncol 4:95-103. 2003
    ..Splenectomy is considered the first-line treatment of choice for splenic MZL; it results in only partial remission, but responses are generally sufficient for correcting cytopenia, improving quality of life, and increasing survival...
  75. ncbi request reprint Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
    ..This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas...
  76. ncbi request reprint High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial
    Danielle Canioni
    Department of Pathology, Assistance Publique Hopitaux de Paris, Hopital Necker Enfants Malades, Universite Paris Descartes, 149 rue de Sevres, 75015, Paris, France
    J Clin Oncol 26:440-6. 2008
    ..We tried to establish whether intratumoral macrophage count (MC) definitely is able to predict the outcome of FL patients in the rituximab era...
  77. ncbi request reprint [News in therapeutic management of chronic lymphoid leukemia]
    Anne Sophie Michallet
    Hopital Edouard Herriot, Place d Arsonval, 69437 Lyon Cedex 03
    Bull Cancer 92:249-56. 2005
    ..In parallel, age, co morbidities and the notion of the risk-adapted strategy have also an important impact adding...
  78. ncbi request reprint [Pathological and clinical correlations in primary cutaneous B-cell lymphomas: a series of 44 cases]
    Arnaud de la Fouchardiere
    Service d Anatomie Pathologique, Hopital Croix Rousse, Lyon
    Ann Pathol 25:8-17. 2005
    ..histological and clinical relationship study of 44 cases of primary cutaneous B cell lymphoma, classified according to WHO classification...
  79. ncbi request reprint Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
    Sylvain Choquet
    Hematology Unit, CHU La Pitié Salpêtrière Hospital, 47 bd de l Hopital, 75651 Paris Cedex 14, France
    Blood 107:3053-7. 2006
    ..We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments...
  80. ncbi request reprint The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas
    Eva M Murga Penas
    University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Haematologica 92:405-9. 2007
    ..FISH revealed the involvement of the immunoglobulin locus in the t(11;14;18). Rapid amplification of cDNA ends (RACE)-PCR to detect the involved partner gene on 6q showed exclusively wild-type API2 and MALT1 sequences...
  81. ncbi request reprint T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Pierre Raynaud
    Department of Hematology and Pathology, INSERM 475 and CHU 34295 Montpellier, France
    Hum Pathol 39:194-200. 2008
    ....
  82. ncbi request reprint Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de
    Catherine Sebban
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Blood 108:2540-4. 2006
    ..After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients...
  83. ncbi request reprint Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study
    Jean Henri Bourhis
    Division of Hematology, Department of Medicine, Institut Gustave Roussy, 94800 Villejuif, France
    Haematologica 92:1083-90. 2007
    ....
  84. ncbi request reprint Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte
    René Olivier Casasnovas
    Service d Hematologie Clinique, Hopital Le Bocage, Centre Hospitalier Universitaire Dijon, Dijon, France
    J Clin Oncol 25:1732-40. 2007
    ..Usual prognosis scoring systems are actually unable to identify this small subset of patients with good confidence, pointing out the need for additional prognostic biomarkers...
  85. ncbi request reprint Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium
    Daphne de Jong
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 25:805-12. 2007
    ....
  86. ncbi request reprint Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma
    Jacek Nowak
    Institute of Haematology and Blood Transfusion, Warsaw, Poland
    Genes Chromosomes Cancer 46:500-7. 2007
    ..We conclude that 8.1 AH is an important contributor to NHL outcome. In contrast to A*01-B*08-TNF(-308A, the remaining alleles (Cw*07, DRB1*03, LTA+252G) associated with the 8.1 AH seem to be its passive components...
  87. ncbi request reprint Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome
    Przemyslaw Juszczynski
    Department of Hematology and Department of Clinical Immunology, Medical University of Lodz, Poland
    Blood 100:3037-40. 2002
    ..63; P <.0001, RR = 1.51) and null HLA DRB1*02 alleles (P =.015, RR = 1.18; P <.0001, RR = 1.25) as independent factors for FFP and OS. These results indicate the existence of at least 2 inherited factors involved in NHL outcome...
  88. ncbi request reprint The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell
    Lucile Baseggio
    Haematologica 91:1717-9. 2006
    ..Interestingly, with the use of an appropriate antibody association, this feature is easily and rapidly observed on flow cytometry graphics...
  89. ncbi request reprint Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sézary syndrome
    Evelyne Callet-Bauchu
    Haematologica 92:1277-8. 2007
    ..2) translocation. Molecular analyses identified a new transcript, an e8a4 BCR-ABL fusion mRNA which could be responsible for the disease transformation...
  90. ncbi request reprint Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas
    Sidonie Niclot
    Institut National de la Santé et de la Recherche Médicale INSERM UR383 E0210, the Service d Hématologie Clinique adulte U550, and the Département de biostatistiques, Hopital Necker Enfants Malades, Universite Rene Descartes, Paris, France
    Blood 108:278-85. 2006
    ....
  91. ncbi request reprint Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma
    Sophie Gazzo
    Haematologica 90:1708-9. 2005
    ..These data underline that FISH analysis must be be systematically performed in cases with an aberrant presentation to prevent a misdiagnosis...
  92. ncbi request reprint [The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas]
    Przemysław Juszczyński
    Oddział Chorób Rozrostowych, Regionalny Ośrodek Onkologiczny, Wojewódzki Szpital Specjalistyczny im M Kopernika w Lodzi
    Przegl Lek 62:1417-21. 2005
    ..009 and p = 0.017, respectively). These data indicate that innate immunity as reflected by the genetic propensity of the host to regulate TNF expression influences clinical course and outcome of NHL...